ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.9234C>T (p.Val3078=) (rs587782428)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000495698 SCV000578815 likely benign Breast-ovarian cancer, familial 2 2017-06-29 reviewed by expert panel curation Synonymous substitution variant, with low bioinformatic likelihood to result in a splicing aberration (Splicing prior probability 0.02;
Ambry Genetics RCV000131482 SCV000186469 uncertain significance Hereditary cancer-predisposing syndrome 2017-05-31 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient evidence
Invitae RCV000590584 SCV000259605 likely benign not provided 2019-02-11 criteria provided, single submitter clinical testing
Color RCV000131482 SCV000684038 uncertain significance Hereditary cancer-predisposing syndrome 2018-10-12 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000608709 SCV000695219 likely benign not specified 2018-04-27 criteria provided, single submitter clinical testing BRCA2 c.9234C>T alters a non-conserved nucleotide resulting in a synonymous change. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 1.6e-05 in 250876 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.9234C>T has been reported in the literature in individuals affected with Hereditary Breast and Ovarian Cancer in whom co-occurrences with other pathogenic variant(s) have been reported (BRCA1 c.4165_4166delAG, p.Ser1389Terfs), providing supporting evidence for a benign role (Sanz_2010). At least one publication reports experimental evidence evaluating an impact on splicing reporting a partial skipping of exon 24, however, does not allow convincing conclusions about the variant effect as the primary data was not included (Sanz_2010). Seven submitters including one expert panel (ENIGMA) have provided clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple submitters reported the variant with conflicting assessments while the expert panel classifies the variant a likely benign. Based on the evidence outlined above, the variant was classified as likely benign.
GeneDx RCV000608709 SCV000730936 benign not specified 2015-09-14 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Counsyl RCV000495698 SCV000785176 uncertain significance Breast-ovarian cancer, familial 2 2017-05-26 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000590584 SCV000889177 likely benign not provided 2018-04-25 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.